METTL24 and prostate adenocarcinoma: For deep deletion of METTL genes in individual TCGA tumor types, only METTL24 showed deep deletion rates above 5% in diffuse large B-cell lymphoma (DLBC, 10.41%), prostate cancer (PRAD, 8.38%), and uveal melanoma (UVM, 6.25%) (Fig. 1C, Supplementary Table S4).